FIELD: biotechnology.
SUBSTANCE: disclosed is a composition for culturing an isolated CD3-CD56+ natural killer cell containing an effective amount of a fused protein dimer as an active ingredient, where the fusion protein contains the amino acid sequence SEQ ID NO: 9, 26, 28 or 30. Also disclosed are versions of a method for culturing an isolated CD3-CD56+ natural killer cell using said fused protein dimer.
EFFECT: invention provides stimulation of proliferation of natural killer cells, induction of expression of CD16 and NKp46 and increased level of expression and secretion of granzyme B and perforin.
6 cl, 34 dwg, 17 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRUNCATED CHIMERIC RECEPTORS NKG2D AND THEIR WAYS OF USE IN IMMUNOTHERAPY USING NATURAL KILLER CELLS | 2018 |
|
RU2830556C2 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| CRYOPRESERVED CELLS ARE NATURAL KILLERS PRELOADED WITH ANTIBODY CONSTRUCTION | 2019 |
|
RU2819927C2 |
| COMPOSITION FOR CULTURING REGULATORY T-CELLS AND ITS APPLICATION | 2020 |
|
RU2807802C1 |
| POLYVALENT MODULATORS OF REGULATORY T-CELLS | 2017 |
|
RU2769871C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| FUSION PROTEIN COMPRISING IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF | 2021 |
|
RU2831612C1 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT TUMOUR CONTAINING FUSION PROTEIN CONTAINING IL-2 PROTEIN AND CD80 PROTEIN, AND IMMUNE CONTROL POINT INHIBITOR | 2020 |
|
RU2828377C1 |
